Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022
Vyant Bio, a biotechnology company focused on drug discovery for neurodevelopmental and neurodegenerative disorders, announced an investor conference call on May 16, 2022. The call will feature CEO Jay Roberts, CFO Andy LaFrence, and CSO Robert Fremeau, who will provide updates on the company's first-quarter 2022 performance. Vyant Bio leverages human-derived organoid models, machine learning, and advanced screening methods to enhance drug discovery processes, aiming to improve treatment efficacy for conditions like Rett Syndrome and Parkinson’s Disease.
- Host of an investor conference call, indicating proactive investor relations.
- Focus on innovative drug discovery targeting critical CNS disorders.
- Management's commitment to transparency through Q&A sessions during the call.
- No specific financial results or metrics provided for Q1 2022.
- Dependence on future fundraising and partnerships for operational continuation.
CHERRY HILL, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Monday, May 16, 2022.
Jay Roberts, Chief Executive Officer, Andy LaFrence, Chief Financial Officer, and Robert Fremeau, PhD, Chief Scientific Officer, of Vyant Bio will provide an update on the business, scientific, and financial progress made during the first quarter of 2022. Management will also be taking audience questions.
| Event: | Investor Conference Call and Webcast for the First Quarter 2022 |
| Date: | Monday, May 16, 2022 |
| Time: | 4:30pm ET |
| Dial In: | Toll Free: 1.888.506.0062 Conference ID: 109432 |
| Webcast: | https://www.webcaster4.com/Webcast/Page/2756/45406 |
The live event will be recorded and available for replay. The conference call and webcast details are also included inside the Investors section of the Vyant Bio corporate website at www.vyantbio.com.
ABOUT VYANT BIO, INC.
Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nadsaq:VYNT), is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics. Vyant Bio has built a platform of therapeutics seeking to treat neurodevelopmental and neurodegenerative diseases, with current programs targeting Rett Syndrome (“Rett”), CDKL5 Deficiency Disorders (“CDD”), and Parkinson’s Disease. The Company’s approach to drug discovery integrates human-derived biology with artificial intelligence and machine learning technologies to de-risk candidate selection, with the goal of improving the potential effectiveness of drugs discovered earlier in the development cycle. Vyant Bio’s management believes that drug discovery needs to progressively shift to more efficient methods as the widely used models for predicting safe and effective drugs have under-performed, as evidenced by the significant time and cost of bringing novel drugs to market. By combining sophisticated data science capabilities with highly functional human cell derived disease models, Vyant Bio seeks to leverage its current ability to screen and test therapeutic candidates, and create a unique approach to assimilating data that supports decision making iteratively throughout the discovery phase of drug development to identify both novel and repurposed CNS therapeutic candidates.
For more information, please visit or follow Vyant Bio at:
Internet: www.vyantbio.com
LinkedIn: https://www.linkedin.com/company/vyant-bio
Twitter: @VyantBio
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, the efficacy of our drug screening and discovery process, and potential for our services, future revenues or growth in this press release constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability, adapt to the global coronavirus pandemic, raise capital to meet our liquidity needs, and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2021, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.
Investor Contact:
Jennifer K. Zimmons, PhD, MBA
Investor Relations
Zimmons International Communications, Inc.
Email: jzimmons@zimmonsic.com
Phone: +1.917.214.3514
###
FAQ
What is the date of Vyant Bio's investor conference call?
Who is speaking at the Vyant Bio investor conference call?
What is the focus of Vyant Bio's drug discovery platform?
How can I access the Vyant Bio investor conference call?
What are the key conditions targeted by Vyant Bio's programs?
